A detailed history of Euclidean Capital LLC transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Euclidean Capital LLC holds 2,627,643 shares of PMVP stock, worth $3.86 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares
2,627,643
Previous 2,627,643 -0.0%
Holding current value
$3.86 Million
Previous $4.26 Million 8.01%
% of portfolio
0.43%
Previous 0.54%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$6.01 - $8.93 $495,230 - $735,840
82,401 Added 3.24%
2,627,643 $16.1 Million
Q2 2023

Aug 14, 2023

BUY
$3.94 - $6.27 $820,832 - $1.31 Million
208,333 Added 8.91%
2,545,242 $15.9 Million
Q4 2021

Feb 14, 2022

SELL
$19.99 - $30.24 $8.65 Million - $13.1 Million
-432,904 Reduced 15.63%
2,336,909 $54 Million
Q3 2021

Nov 15, 2021

SELL
$26.84 - $36.58 $30.6 Million - $41.7 Million
-1,138,864 Reduced 29.14%
2,769,813 $82.5 Million
Q2 2021

Aug 16, 2021

SELL
$28.01 - $36.01 $7.58 Million - $9.75 Million
-270,739 Reduced 6.48%
3,908,677 $134 Million
Q4 2020

Feb 12, 2021

BUY
$31.86 - $61.51 $133 Million - $257 Million
4,179,416 New
4,179,416 $257 Million

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $67.1M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track Euclidean Capital LLC Portfolio

Follow Euclidean Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Euclidean Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Euclidean Capital LLC with notifications on news.